Skip to main content
Clinical Trials/NCT02027831
NCT02027831
Unknown
Phase 2

Near-infrared Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After Intravenous Injection of Indocyanine Green (a Feasibility Study)

Jules Bordet Institute1 site in 1 country10 target enrollmentDecember 2013

Overview

Phase
Phase 2
Intervention
Indocyanine Green
Conditions
Head and Neck Cancer
Sponsor
Jules Bordet Institute
Enrollment
10
Locations
1
Primary Endpoint
Evaluation of the capacity of ICG to detect cervical lymph nodes after IV injection
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to determine if NIR fluorescent imaging is an effective approach to detect the margins of head and neck tumours or lymph nodes draining the tumour

Detailed Description

Primary objective: definition of the distribution of intravenously injected ICG in the normal and pathological lymph nodes draining the dissected tumor in head and neck cancer patients or in nodes recurrences in head and neck cancer Secondary objectives: * Evaluation of the ability of NIR fluorescence imaging to determine the tumoral volume, specifically the margins of the tumoral tissues (in the operating room and in the pathology department) * Analysis of the correlation between ICG fluorescence and tumoral invasion in the dissected lymph nodes

Registry
clinicaltrials.gov
Start Date
December 2013
End Date
October 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All patients requiring neck dissection with or without resection of the primary (the decision and the type of neck dissection are preliminary decided during head and neck multidisciplinary oncologic consultation).
  • Informed consent form signed.

Exclusion Criteria

  • Age less than18 years old.
  • Inability to give informed consent.
  • History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.
  • Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.
  • Documented coronary disease.
  • Advanced renal impairment (creatinine \> 1,5mg/dl).
  • During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).
  • Pregnancy, breastfeeding

Arms & Interventions

Indocyanine Green

Intravenous injection of 0,25 mg/kg Indocyanine Green

Intervention: Indocyanine Green

Outcomes

Primary Outcomes

Evaluation of the capacity of ICG to detect cervical lymph nodes after IV injection

Time Frame: 7 months

After IV injection of Indocyanine Green just before the surgery to head and neck cancer patients, we will study the fluorescence due to ICG in cervical lymph nodes and in the primary lesion.

Study Sites (1)

Loading locations...

Similar Trials